Franklin FTSE Developed World UCITS ETF IE000CVOSY02 Blend | Factsheet as of 31 January 2025 This is a marketing communication. Please refer to the prospectus of the UCITS and to the KIID before making any final Fund Overview investment decisions.Umbrella Franklin Templeton ICAV This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Fund Base Currency USDFund Inception Date 24/06/2024 Investment OverviewValor Number 136062533 The Fund aims to provide exposure to large and mid-capitalisation stocks in developed market countries globally. The ISINIE000CVOSY02 Fund seeks to track the performance of the FTSE Developed Index NR (the "Index") as closely as possible, regardless Bloomberg DWLD GR of whether the Index level rises or falls, while seeking to minimise as far as possible the tracking error between theDomicile Ireland Fund's performance and that of the Index. UCITS YesProduct StructurePhysical PerformanceReplication Methodology Full ReplicationFrequency of Index Under current legislation, we are not allowed to display performance data with less than a complete 12 month performanceReconstitution Quarterly record.Use of Income AccumulationFiscal Year End 30 JuneShares Outstanding 300,000 Benchmark(s) and TypeFTSE Developed Index-NR Comparator ChargesTotal Expense Ratio 0.09% The charges are the fees the Fund charges to investors to coverthe costs of running the Fund. Additional costs, includingtransaction fees, will also be incurred. These costs are paid out bythe Fund, which will impact on the overall return of the Fund. Fundcharges will be incurred in multiple currencies, meaning thatpayments may increase or decrease as a result of currencyexchange fluctuations. Fund Characteristics Fund BenchmarkTotal Net Assets $8.28 MillionNumber of Holdings1,428Price to Book 3.29x3.40xPrice to Earnings (12-MonthTrailing)22.94x 22.98x Franklin FTSE Developed World UCITS ETF as of 31 January 2025 Top Equity Issuers (% of Total)Trading Information Fund Exchange Ticker CurrencyBloomberg Reuters SEDOL APPLE INC 4.63 Borsa ItalianaWORLDEURWORLD IM WRLDF.MI BSGYZW8 MICROSOFT CORP4.22 Deutsche Börse Xetra DWLDEUR DWLD GR DWLDG.DE BSGYZT5 NVIDIA CORP 3.84 Euronext Paris Exchange WORLDEURWORLD FP WORLDF.PA BSLMXX4 AMAZON.COM INC3.02 London Stock Exchange WORLGBP WORL LN WORL.L BMWGKK9 ALPHABET INC 3.01 London Stock Exchange DWLDUSD DWLD LN DWLD.L BSGYZR3 META PLATFORMS INC2.06 SIX Swiss Exchange DWLDUSD DWLD SW DWLD.S BSB7S34 TESLA INC 1.52 BROADCOM INC 1.37Portfolio Management BERKSHIRE HATHAWAY INC 1.17 Years with FirmYears of Experience JPMORGAN CHASE & CO 1.05 Dina Ting, CFA9 29Lorenzo Crosato, CFA 7 26 Geographic Allocation (% of Total)What are the Risks? Fund Benchmark United States 71.38 71.43 The Fund does not offer any capital guarantee or protection and you may not get back the amount invested. The Fund is subject to the Japan 6.26 6.23 following risks which are materially relevant: Index Tracking Risk: No financial instrument or set of investment techniques enables the United Kingdom 3.49 3.79 returns of any Index to be reproduced or trackedexactly. Changes in the investments of any Sub-Fund and re-weightings ofthe relevantIndex may give rise to various transaction costs, operatingexpenses or inefficiencies which may adversely impact a Sub-Fund'stracking of Canada 2.62 2.63an Index. Index License Risk: To utilise an Index, the Fund may need to have alicence agreement signed with the Index Provider. If, at France 2.55 2.57 any time in respectof an Index, the licence granted terminates or disputed, impaired or ceasesto exist ,the Directors may be forced to Germany 2.21 2.25 replace the Index with another Index.Such a substitution or any delay in such a substitution may have an adverseimpact on the Sub-Fund. Australia 2.03 1.91 Passive Investment Risk: An Index Tracking Sub-Fund will be negativelyaffected by general declines in the securities and asset classes Switzerland2.02 2.30 representedin its Index. Because Index Tracking Sub-Funds are not “actively”managed,Market disruptions and regulatory restrictions Others 7.376.89 could have an adverse effecton an Index Tracking Sub-Fund's ability to adjust its exposure to the requiredlevels. Cash & Cash Equivalents0.06 0.00 Complete information on the risks of investing in the Fund are set out in the Fund's prospectus. Glossary Sector Allocation (% of Total) Total Expense Ratio: Total Expense Ratio (TER) includes the fees paid to the management company, the investment manager and the Fund Benchmark depository, as well as certain other expenses. The TER is calculated by taking the relevant main material costs paid out over the 12-month Information Technology24.67 24.68 period indicated and dividing them by the average net assets over the same period. The TER does not include all expenses paid by the Financials16.88 16.88 fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs Consumer Discretionary 11.30 11.29 deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that showthe effects that different levels of return could have on an investment in the fund, where applicable, see the KIID. For funds that lack 12 Industrials10.7710.77months of data, or for which TER is not likely to give a fair idea of likely future costs, the figure shown is an estimate. Product Structure: Health Care 10.50 10.52The Product Structure indicates whether an ETF is holding physical securities (i.e. Physical) or whether it is tracking the index performance Communication Services 8.37 8.39 using derivatives (swaps, i.e. Synthetic). Methodology: The Methodology indicates whether an ETF is holding all index securities in the Consumer Staples5.95 5.97 same weight as the index (i.e. Physical Replication) or whether an optimised subset of index securities is used (i.e. Optimised) in order to Energy 3.58 3.57 efficiently track index performance. Comparator: Benchmark is used for comparing Fund performance, but is not a constraint to Fund Others 7.93 7.94 Investment. Price to Book: The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value Cash & Cash Equivalents0.06 0.00 represents a weighted average of the stocks it holds. Price to Earnings (12-Month Trailing) is the share price of a stock, divided by itsper-share earnings over the past year. For a portfolio, the value represents a weighted average of the stocks it holds. Market Cap Breakdown (% of Equity) (USD) Portfolio Data Information Fund Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities 2.0-5.0 Billion 1.00 mentioned. 5.0-10.0 Billion 2.62 10.0-25.0 Billion 8.63 25.0-50.0 Billion12.58 >50.0 Billion75.04 N/A 0.13 Franklin FTSE Developed World UCITS ETF as of 31 January 2025 Important Information This is a sub-fund ("Fund") of Franklin Templeton ICAV, an Irish collective asset-management vehicle. An investment in Franklin Templeton ICAV entails risks which are described in the latest prospectus or supplement and in the KIID. The Fund's documents are available in English, German and French from your local website or can be requested via FT's European Facilities Service available at www.eifs.lu/franklintempleton. In addition, a Summary of Investor Rights is available from www.franklintempleton.lu/summary-of-investor-rights. The summary is available in English. Franklin Templeton ICAV is notified for marketing in multiple EU Member States under the UCITS Directive. Franklin Templeton ICAV can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive. For the avoidance of doubt, if you decide to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund. Given the variety of investment options available today, we suggest investors seek guidance from a Financial Adviser. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. The Sub-Fund has been developed solely by Franklin Templeton. The Sub-Fund is not in any way connected to or sponsored, endorsed, sold or promoted by the London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). FTSE Russell is a trading name of certain of the LSE Group companies. All rights in the FTSE Russell Index (the "Index") vest in the relevant LSE Group company which owns the Index. "FTSE®" "Russell®", "FTSE Russell®", "MTS®", "FTSE4Good®", "ICB®" and "The Yield Book®," are trade mark(s) of the relevant LSE Group company and are used by any other LSE Group company under license. "TMX®" is a trade mark of TSX, Inc. and used by the LSE Group under license. The Index is calculated by or on behalf of FTSE International Limited or its affiliate, agent or partner. The LSE Group does not accept any liability whatsoever to any person arising out of (a) the use of, reliance on or any error in the Index or (b) investment in or operation of the Sub-Fund. The LSE Group makes no claim, prediction, warranty or representation either as to the results to be obtained from the Sub-Fund or the suitability of the Index for the purpose to which it is being put by Franklin Templeton. Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges. Important data provider notices and terms available at www.franklintempletondatasources.com. Issued by Franklin Templeton Investment Management Limited (FTIML) Registered office: Cannon Place, 78 Cannon Street, London EC4N 6HL.ßTIML is authorised and regulated by the Financial Conduct Authority. UK Freephone: 0800 305 306 | email: enquiries@franklintempleton.co.uk | www.franklintempleton.co.uk